N
UBX

Nuveen’s Unity Biotechnology UBX Stock Holding History

Nuveen’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-13,644
Closed -$819K – 3534
2021
Q1 		$819K Buy
13,644
+2,397
+21% +$163K ﹤0.01% 2954
2020
Q4 		$589K Buy
11,247
+352
+3% +$17K ﹤0.01% 2998
2020
Q3 		$1.35M Sell
10,895
-4,993
-31% -$316K ﹤0.01% 2552
2020
Q2 		$1.38M Buy
15,888
+4,993
+46% +$370K ﹤0.01% 2485
2020
Q1 		$632K Buy
10,895
+1,136
+12% +$71.6K ﹤0.01% 2692
2019
Q4 		$703K Sell
9,759
-84
-0.9% -$5.93K ﹤0.01% 2815
2019
Q3 		$601K Sell
9,843
-482
-5% -$34.1K ﹤0.01% 2884
2019
Q2 		$981K Buy
+10,325
New +$878K ﹤0.01% 2745

Other funds holding UBX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
MC
Mayo Clinic Rochester, Minnesota $2.9M AUM 14.49% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IFA
Invus Financial Advisors New York $89.2M AUM 10.79% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Nuveen's UBX Position: Q2 2021 in Review

Nuveen sold out of Unity Biotechnology (UBX) in Q2 2021, closing a stake of 13,644 shares — an estimated $819K sold.

Nuveen first reported a position in UBX in Q2 2019 and held it in 8 quarters. The position peaked at $1.38M in Q2 2020. 98 funds tracked by Wall St. Rank hold UBX as of Q2 2021.

  • Nuveen reported no remaining Unity Biotechnology position as of Q2 2021 after selling out during the quarter.
  • Nuveen sold 13,644 Unity Biotechnology shares in Q2 2021, an estimated $819K.
  • Nuveen first reported a position in Unity Biotechnology in Q2 2019 and held it in 8 quarters.
  • Nuveen's Unity Biotechnology position peaked at $1.38M in Q2 2020.
  • 98 funds tracked by Wall St. Rank held Unity Biotechnology as of Q2 2021.

Based on Nuveen's 13F filing for Q2 2021, filed 16 Aug 2021.